MX2020007366A - Composiciones y metodos para tratar trastornos de la retina. - Google Patents
Composiciones y metodos para tratar trastornos de la retina.Info
- Publication number
- MX2020007366A MX2020007366A MX2020007366A MX2020007366A MX2020007366A MX 2020007366 A MX2020007366 A MX 2020007366A MX 2020007366 A MX2020007366 A MX 2020007366A MX 2020007366 A MX2020007366 A MX 2020007366A MX 2020007366 A MX2020007366 A MX 2020007366A
- Authority
- MX
- Mexico
- Prior art keywords
- retina
- compositions
- methods
- treating disorders
- cone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1800546.2A GB201800546D0 (en) | 2018-01-12 | 2018-01-12 | Treatment |
| PCT/GB2019/050092 WO2019138250A1 (en) | 2018-01-12 | 2019-01-14 | Compositions and methods for treating retinal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007366A true MX2020007366A (es) | 2020-09-03 |
Family
ID=61256183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007366A MX2020007366A (es) | 2018-01-12 | 2019-01-14 | Composiciones y metodos para tratar trastornos de la retina. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11680276B2 (https=) |
| EP (1) | EP3737423B1 (https=) |
| JP (1) | JP7289306B2 (https=) |
| KR (1) | KR102786552B1 (https=) |
| CN (1) | CN111936172A (https=) |
| AU (1) | AU2019206314B2 (https=) |
| BR (1) | BR112020014191A2 (https=) |
| CA (1) | CA3088079A1 (https=) |
| DK (1) | DK3737423T3 (https=) |
| EA (1) | EA202091655A1 (https=) |
| ES (1) | ES2988499T3 (https=) |
| FI (1) | FI3737423T3 (https=) |
| GB (1) | GB201800546D0 (https=) |
| HR (1) | HRP20241483T1 (https=) |
| HU (1) | HUE068987T2 (https=) |
| IL (1) | IL275985A (https=) |
| LT (1) | LT3737423T (https=) |
| MX (1) | MX2020007366A (https=) |
| PH (1) | PH12020551071A1 (https=) |
| PL (1) | PL3737423T3 (https=) |
| PT (1) | PT3737423T (https=) |
| RS (1) | RS66227B1 (https=) |
| SG (1) | SG11202006618PA (https=) |
| SI (1) | SI3737423T1 (https=) |
| SM (1) | SMT202400410T1 (https=) |
| WO (1) | WO2019138250A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230058556A (ko) | 2013-03-15 | 2023-05-03 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 만능 줄기 세포로부터 제조된 광수용기 및 광수용기 전구체 |
| US11241460B2 (en) | 2013-03-15 | 2022-02-08 | Astellas Institute For Regenerative Medicine | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
| GB2584664B (en) * | 2019-06-10 | 2023-05-24 | Newcells Biotech Ltd | Improved retinal organoids and methods of making the same |
| CN113025616B (zh) * | 2021-04-21 | 2023-05-02 | 中国热带农业科学院橡胶研究所 | 一种橡胶树泛素基因启动子proHbUBI2及其克隆与应用 |
| CN118076629A (zh) * | 2021-05-20 | 2024-05-24 | 阿特玛治疗公司 | Kcnv2变体及其用途 |
| WO2023039175A2 (en) * | 2021-09-09 | 2023-03-16 | Applied Genetic Technologies Corporation | Predictors of achromatopsia treatment efficacy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
| WO2011034947A2 (en) * | 2009-09-15 | 2011-03-24 | University Of Washington | Reagents and methods for modulating cone photoreceptor activity |
| EP3591055A1 (en) * | 2011-01-07 | 2020-01-08 | Applied Genetic Technologies Corporation | Promoters derived from the 5' nontranslated region (5'-ntr) of the human cyclic nucleotide gated beta 3 (cngb3) gene, expression cassettes and vectors comprising said promoters, for use treating achromatopsia and other diseases |
| KR102537394B1 (ko) * | 2014-03-17 | 2023-05-30 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 |
| MY187898A (en) * | 2015-03-02 | 2021-10-27 | Adverum Biotechnologies Inc | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| WO2017144080A1 (en) | 2016-02-23 | 2017-08-31 | Eyeserv Gmbh | Gene therapy for the treatment of a disease of retinal cone cells |
-
2018
- 2018-01-12 GB GBGB1800546.2A patent/GB201800546D0/en not_active Ceased
-
2019
- 2019-01-14 PT PT197010184T patent/PT3737423T/pt unknown
- 2019-01-14 HU HUE19701018A patent/HUE068987T2/hu unknown
- 2019-01-14 KR KR1020207023349A patent/KR102786552B1/ko active Active
- 2019-01-14 BR BR112020014191A patent/BR112020014191A2/pt unknown
- 2019-01-14 DK DK19701018.4T patent/DK3737423T3/da active
- 2019-01-14 AU AU2019206314A patent/AU2019206314B2/en active Active
- 2019-01-14 PL PL19701018.4T patent/PL3737423T3/pl unknown
- 2019-01-14 MX MX2020007366A patent/MX2020007366A/es unknown
- 2019-01-14 HR HRP20241483TT patent/HRP20241483T1/hr unknown
- 2019-01-14 CA CA3088079A patent/CA3088079A1/en active Pending
- 2019-01-14 CN CN201980018443.4A patent/CN111936172A/zh active Pending
- 2019-01-14 JP JP2020538584A patent/JP7289306B2/ja active Active
- 2019-01-14 RS RS20241186A patent/RS66227B1/sr unknown
- 2019-01-14 SI SI201930833T patent/SI3737423T1/sl unknown
- 2019-01-14 EP EP19701018.4A patent/EP3737423B1/en active Active
- 2019-01-14 LT LTEPPCT/GB2019/050092T patent/LT3737423T/lt unknown
- 2019-01-14 SG SG11202006618PA patent/SG11202006618PA/en unknown
- 2019-01-14 FI FIEP19701018.4T patent/FI3737423T3/fi active
- 2019-01-14 ES ES19701018T patent/ES2988499T3/es active Active
- 2019-01-14 US US16/961,857 patent/US11680276B2/en active Active
- 2019-01-14 EA EA202091655A patent/EA202091655A1/ru unknown
- 2019-01-14 SM SM20240410T patent/SMT202400410T1/it unknown
- 2019-01-14 WO PCT/GB2019/050092 patent/WO2019138250A1/en not_active Ceased
-
2020
- 2020-07-10 PH PH12020551071A patent/PH12020551071A1/en unknown
- 2020-07-12 IL IL275985A patent/IL275985A/en unknown
-
2023
- 2023-06-16 US US18/336,409 patent/US12467066B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007366A (es) | Composiciones y metodos para tratar trastornos de la retina. | |
| ZA202502751B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| WO2016172658A3 (en) | Microbiome regulators and related uses thereof | |
| MX2018011114A (es) | Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías. | |
| SG11201802145SA (en) | Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders | |
| MX2023005484A (es) | Analogos de carbamoil fenilalaninol y usos de los mismos. | |
| BR112017012581A2 (pt) | tratamento de degeneração da retina com o uso de células progenitoras | |
| EA201990257A1 (ru) | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением | |
| PH12019500751A1 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| PH12018502318A1 (en) | Compositions and methods for treatment of inflammation of infection of the eye | |
| PH12018502704A1 (en) | Treatment of retinal vascular disease using progenitor cells | |
| PH12017500500A1 (en) | C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions | |
| WO2015113041A3 (en) | Compositions and methods for treating autoimmune and inflammatory diseases | |
| MX2016010967A (es) | Nuevas composiciones para tratar lesiones neuronales mecanicas. | |
| MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci | |
| HK1237265A1 (en) | Combination therapy compositions and methods for treating cancers |